NILVANSTOMIG
UNII 2NQG7P8ET6

Substance Identification & Data

This profile provides standardized clinical and technical data for Nilvanstomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2NQG7P8ET6.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061475-22-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2NQG7P8ET6

CAS Registry Number

3061475-22-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NILVANSTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C208073

National Cancer Institute reference terminology for clinical and research data.

INN ID

13880

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Nilvanstomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nilvanstomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Nilvanstomig

Common Names & Synonyms

H-gamma4 heavy chain anti-PDCD1 fused to a scFvhk anti-TIGIT (H) (1-713) [H-gamma4 heavy chain anti-PDCD1 humanized (1-444) [VH (Homo sapiens IGHV1-46*01 (85.6%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10 (CH1 (118-215), hinge 1-12 S10>P (225) (216-227), CH2 L92 (306) (228-337), CH3 (338-442), CHS (443-444)) (118-444)] -10-mer bis(tetraglycyl-seryl) linker (445-454) -scFvhk anti-TIGIT humanized (455-713) [VH (Homo sapiens IGHV1-46*01 (98.0%) -IGHD -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (480-487.505-512.551-565)) (455-576) -30-mer hexakis(tetraglycyl-seryl) linker (577-606) -V-KAPPA (Homo sapiens IGKV1-39*01 (93.7%) -IGKJ1*01 (100%), CDR-IMGT[6.3.9] (633-638.656-658.695-703)) (607-713)]]; (131-214')-disulfide with L-kappa light chain anti-PDCD1 humanized (L') (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*01 (84.2%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (223-223'':226-226'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin G4, bispecific, anti-(human/Macaca fascicularis programmed cell death protein 1) (human-Mus musculus monoclonal 2P17 γ4-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human/Macaca fascicularis receptor TIGIT) (human-Mus musculus monoclonal B21-35 single-chain variable fragment VH-(GGGGS)6-VL), disulfide with human-Mus musculus monoclonal 2P17 κ-chain, dimer

immunoglobulin (H-gamma4-scFvhk_L-kappa) dimer, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)] and anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody, bispecific, tetravalent (nilvanstomig)

nilvanstomig [INN]

External Clinical & Regulatory Resources

Previous UNII2NQ8WWR2PX

Next UNII2NQN80556Q